logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produswest2
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produswest2
Showing 1 - 7 of 7 Items
Showing 1 - 7 of 7 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Protocol

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M,  et al.
2023-11-30 • Trials
2023-11-30 • Trials
BACKGROUND
Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...
Journal Article
|
Review

Recent advances in the treatment of tuberculosis

Motta I, Boeree M, Chesov D, Dheda K, Günther G,  et al.
2023-07-21 • Clinical Microbiology and Infection
2023-07-21 • Clinical Microbiology and Infection
BACKGROUND
Tuberculosis is a global health challenge and one of the leading causes of death worldwide. In the last decade, the tuberculosis treatment landscape has dramatically chang...
Journal Article
|
Research

The Epidemiology, Pathogenesis, Transmission, Diagnosis, and Management of Multidrug-Resistant, Extensively Drug-Resistant, and Incurable Tuberculosis

Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R,  et al.
2017-03-15 • Lancet Respiratory Medicine
2017-03-15 • Lancet Respiratory Medicine
Global tuberculosis incidence has declined marginally over the past decade, and tuberculosis remains out of control in several parts of the world including Africa and Asia. Although tube...
Journal Article
|
Protocol

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E,  et al.
2021-09-25 • Trials
2021-09-25 • Trials
BACKGROUND
Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. W...
Journal Article
|
Research

Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis

Cohen K, van Cutsem G, Boulle AM, McIlleron HM, Goemaere E,  et al.
2008-02-01 • Journal of Antimicrobial Chemotherapy
2008-02-01 • Journal of Antimicrobial Chemotherapy
BACKGROUND AND OBJECTIVES: Nevirapine-containing antiretroviral therapy (ART) and rifampicin-based antitubercular therapy are commonly co-administered in Africa, where nevirapine is ofte...
Journal Article
|
Review

Towards early inclusion of children in tuberculosis drugs trials: a consensus statement

Nachman S, Ahmed AO, Amanullah F, Becerra M, Botgros R,  et al.
2015-06-01 • Lancet Infectious Diseases
2015-06-01 • Lancet Infectious Diseases
Children younger than 18 years account for a substantial proportion of patients with tuberculosis worldwide. Available treatments for paediatric drug-susceptible and drug-resistant tuber...
Journal Article
|
Commentary

Principles for designing future regimens for multidrug-resistant tuberculosis

Brigden G, Nyang'wa BT, du Cros PAK, Varaine FFV, Hughes J,  et al.
2014-01-01 • Bulletin of the World Health Organization
2014-01-01 • Bulletin of the World Health Organization
Fewer than 20% of patients with multidrug-resistant (MDR) tuberculosis are receiving treatment and there is an urgent need to scale up treatment programmes. One of the biggest barriers t...